Item 2.02 Results of Operations and Financial Condition.

On November 4, 2021, Magenta Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

On November 4, 2021, the Company announced upcoming data presentations at the 2021 American Society of Hematology ("ASH") Annual Meeting. The full text of the press release issued in connection with the announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit 99.1 relating to Item 2.02 shall be deemed furnished, and not filed.





99.1      Press Release dated November 4, 2021 (earnings release).

99.2      Press Release dated November 4, 2021 (ASH Annual Meeting updates).

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses